Tuesday, June 30, 2020

JB CHEMICALS & PHARMACEUTICALS LTD - EARNINGS PRESENTATION Q4 FY 20


JB CHEMICALS & PHARMACEUTICALS LTD

EARNINGS PRESENTATION Q4 FY 20


 Jyotindra B Mody           :            Chairman & Managing Director
  Shirish B Mody                     :     Whole Time Director - Marketing
  Pranabh Mody                      :     WholeTime Director & President
JB Chemicals and Pharmaceuticals (in Rs. Cr.)
Mar '20
Dec '19
Sep '19
Jun '19
Mar '19
YOY
QOQ
Net Sales
443.57
428.63
456.42
446.11
418.92
5.88
3.49
P/L Before Exceptional Items & Tax
77.02
88.37
101.51
91.99
68.28
12.8
-12.84
Exceptional Items
-10
--
--
--
--


P B T
67.02
88.37
101.51
91.99
68.28
-1.85
-24.16
Tax
16.95
21.93
7.75
29.87
21.49
-21.13
-22.71
Net Profit
50.07
66.45
93.76
62.11
46.79
7.01
-24.65
Equity
15.46
16.05
16.05
16.05
16.05
-3.68
-3.68
Basic EPS (FV :RS.2)
6.3
8.26
11.67
7.73
5.68
10.92
-23.73
MP


701.00
Jun 29, 15:14

Volume


262,964




PE
27.81746






52 Wk L/H
321.7
743





Valuation






Market Cap (Rs Cr.)






5,427.91







P/E
20.2














Book Value (Rs)
187.01













Dividend (%)
550





Industry P/E
31.26













EPS (TTM)

34.7





Price/Book
3.76













Dividend Yield.(%)
1.57













Face Value (RS)
2






·       JB PHARMA’S 4 BRANDS ARE AMONGST TOP 300 IPM BRANDS IN INDIA

·       WORLD CLASS MANUFACTURING FACILITIES WITH APPROVALS LIKE USFDA AND EUGMP

·       WELL DIVERSIFIED ACROSS DIFFERENT EXPORT GEOGRAPHIES

·       CONSISTENT DIVIDEND TRACK RECORD

·       STRONG CASH FLOWS

·       DEBT FREE COMPANY

·       STRATEGIC FOCUS ON CHRONIC SEGMENT

·       OVER 2000 DOMESTIC FIELD FORCE

·      Mfg facilities are located  in Gujarat and Daman with USFDA approved tablet plant and API Plants

·      Ranked 34th as per IQVIA & ranked 19th in Rxns.

·      Domestic Formulations : 42%

·      Branded Generic Esports : 31%

·      CMO 10%

·      US Generics 8%

·      API 4%

·      Contrast Media   3%

·      Others    2%

Q4 FY 20- OPERATIONAL HIGH LIGHTS

1.  DOMESTIC FORMULATIONS BUSINESS REGISTERED GROWTH OF 24% YOY

2.  EXPORT BUSINESS GOT AFFECTED DUE TO LOCK DOWN DURING MARCH END AND DECLINED BY 6% YOY

3.  GROWTH IN  ANDA  BUSINESS GOT AFFECTED DUE TO API SUPPLY ISSUE AT VENDOR LOCATION

4.  MARGIN IMPROVEMENT DUE TO BETTER PRODUCE MIX AND COST OPTIMISATION - HELPED IMPROVE THE OPERATING PROFIT DURING THE FINANCIAL YEAR

5.  COMPANY OPTED FOR LOWER RATE OF TAX OF 25.17% AS PER SEC. 115BAA

6.  MADE PROVISION OF RS.10 CR FOR COMPENSATION ORDERED BY SC JUDGMENT DT 1-4-2020

7.  RECOMMENDED FINAL DIVIDEND OF Rs.1/SHARE FOR FY 20. HAD DECLARED INTERIM DIVIDEND OF RS.10/SH IN MAR 2020

8.  CONSEQUENT TO CURRENT PANDEMIC, COMPANY HAS EXPERIENCED SLOW DOWN IN THE SALE OF PRODUCTS IN ACUTE SEGMENT DUE TO CLOSURE OF CLINICS AND USE OF HOSPITALS LARGELY FOR COVID PATIENTS. THIS COULD ALSO IMPACT PERFORMANCE OF THE LAUNCH OF NEW PRODUCTS.

9.   FY 20 PARTICULARS           FY 20      FY 19      YOY
10.                   OPERATING REVENUE 1774.7  1643.2   8%
11.                   EBITDA                           377.5      305.8      4.5%
12.                   EBITDA MARGIN          21.27%  18.61%  266BPS
13.                   PBT                                 348.9      287.0      21.6%
14.                   PAT                                 272.4      194.0      40.4%
15.                   PAT MARGIN%             15.35%  11.81%  354 BPS
16.                   BASIC EPS                      34.20%  23.54      45.3%

SHARE HOLDING PATTERN AS ON 31ST MARCH

PROMOTERS                 56%
PUBLIC                           23%
MF/INSURANCE           13%
FPI/AIF                           8%

                               



No comments:

Post a Comment